抗精神病药治疗急性精神分裂症的疗效与耐受性:网络荟萃分析
该网络荟萃分析纳入438项随机对照试验,比较23种多巴胺受体阻断剂与毒蕈碱受体激动剂xanomeline-trospium对急性精神分裂症的疗效与耐受性。部分多巴胺激动剂耐受性更好,xanomeline-trospium无多巴胺阻断剂不良反应但有胆碱能相关事件。
要点
- 氯氮平、氨磺必利、奥氮平、利司培酮疗效优于至少三种其他药物。
- 部分多巴胺激动剂总体耐受性更好,xanomeline-trospium有胆碱能不良反应。
核心结论
- 抗精神病药之间存在小到中等临床相关疗效差异,指南应更强调此点。
- 耐受性差异需考虑以个体化选药,部分多巴胺激动剂总体耐受性更好。
- xanomeline-trospium无多巴胺阻断剂不良反应,但导致胆碱能及抗胆碱能不良事件。
研究设计与样本
- 系统综述与随机效应频率学网络荟萃分析(PROSPERO CRD42022380708)。
- 纳入438项随机对照试验,比较23种多巴胺受体阻断剂与xanomeline-trospium不同应用。
主要发现
- 氯氮平、氨磺必利、奥氮平和利培酮疗效优于至少三种其他抗精神病药(估计置信度低至中等)。
- 不良反应因药物而异。
关键数值与推荐
- 主要结局为评定量表测量的精神分裂症总体症状(疗效),采用随机效应频率学网络荟萃分析。
- 次要结局包括32项其他疗效和耐受性结局。
- 采用CINeMA方法评估估计置信度。
临床怎么用
- 临床选药需权衡疗效差异与耐受性差异,实现个体化治疗。
- 部分多巴胺激动剂总体耐受性更好,可考虑用于特定患者。
- xanomeline-trospium无多巴胺阻断剂不良反应,但需监测胆碱能及抗胆碱能不良事件。
局限性
- 多数中国试验因作者未回复或报告严重方法学问题被排除。
- 疗效比较的估计置信度为低至中等。
- 需未来直接比较xanomeline-trospium与其他抗精神病药以确认疗效。
- 需现代试验早期使用氯氮平以确定是否改善结局并预防慢性化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antipsychotic drugs are the established treatment for acute schizophrenia but differ in receptor-binding profiles. In 2024, a new-in-class muscarinic receptor agonist (xanomeline-trospium) was licenced, acting upstream of antidopaminergic agents, and providing hope to decrease the adverse effects burden of antipsychotics. We aimed to compare the efficacy and tolerability of antipsychotics by performing network meta-analysis of randomised controlled trials (RCTs). METHODS: This systematic review (PROSPERO, CRD42022380708) included blinded and open RCTs investigating antipsychotic drugs in participants of any age with acute psychotic symptoms of schizophrenia over 3 weeks to 3 months. Included antipsychotics comprised 23 primarily dopamine-receptor blocking medications and the muscarinic receptor agonist xanomeline-trospium in different applications. We searched Cochrane Schizophrenia group's register, previous reviews, and five Chinese databases for trials published from database inception until July 26, 2024 and contacted authors to assess trials' methodological quality; only trials with appropriate randomisation indicated were included. The primary outcome was rating scale-measured overall symptoms of schizophrenia (efficacy) analysed with random-effects frequentist network meta-analysis. Secondary outcomes comprised 32 further efficacy and tolerability outcomes. The confidence in the estimates was assessed using the Confidence in Network Meta-Analysis approach. FINDINGS: After screening 18 859 references and contacting authors of 5428 trials, we included 438 RCTs. Of those, 388 RCTs with 78 193 participants (28 448 women and 49 745 men) provided usable data for at least one outcome. 5117 Chinese trials were identified but most were excluded because authors did not reply or reported serious methodological concerns. 256 double-blind studies with 58 948 participants provided usable data for the primary outcome. All antipsychotics reduced symptoms more than placebo with standardised mean differences ranging from -0·90 (95% CI -1·03 to -0·77) to -0·23 (-0·39 to -0·06). Particularly clozapine, as well as amisulpride, olanzapine, and risperidone were more efficacious than at least three other antipsychotics (confidence in estimates were low-to-moderate). Adverse effects varied across medications. INTERPRETATION: This network meta-analysis provides evidence for small-to-medium clinically relevant differences between antipsychotics in efficacy; this finding warrants stronger and more specific emphasis in clinical guidelines. Nonetheless, important differences in tolerability need to be considered for individualised drug choice, with partial dopamine agonists having overall better tolerability and xanomeline-trospium lacking adverse effects of dopamine-blocking agents but resulting in cholinergic and anticholinergic adverse events. Future research should directly compare xanomeline-trospium with other antipsychotics to confirm its efficacy; modern trials using clozapine early in schizophrenia are needed to establish whether it improves outcomes and prevents chronification. FUNDING: German Research Foundation, German Ministry of Research, Technology and Space, and National Natural Science Foundation of China.
引用
- Schneider-Thoma J, Zhu Y, Qin M, et al. Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases. Lancet. 2026. PMID: 41763745. doi:10.1016/S0140-6736(25)02365-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。